戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 so identified epitopes unique to each Dengue serotype.
2 d loops that differ in sequence depending on serotype.
3  age, sex, disease severity, and enterovirus serotype.
4 pecific antibody responses against each DENV serotype.
5 ere a pneumococcal conjugate vaccine (PCV13) serotype.
6 ed with the prevalence of resistance in that serotype.
7 (0.25-0.69) for that caused by 3, 6A and 19A serotypes.
8 ions in pneumococcal disease caused by these serotypes.
9 sal swabs, and (iii) the distribution of GBS serotypes.
10 ; 6 of the 21 MAbs neutralized three or more serotypes.
11 nd postbooster (D301) doses for pneumococcal serotypes.
12 vity from mouse sera immunized with parental serotypes.
13 highly penetrant viruses with cross-reactive serotypes.
14  the nucleolus do not colocalize for all the serotypes.
15 o process P1 polyproteins from multiple FMDV serotypes.
16 pneumococcal disease (IPD) caused by vaccine serotypes.
17  provide long-term immunity against all four serotypes.
18  a dangerous strain among 225 E. coli unique serotypes.
19 lly enhance infection by heterologous Dengue serotypes.
20 ver, mAb 2E8 recognizes NS1 of all four DENV serotypes.
21 ional antibody responses against all vaccine serotypes.
22  with representatives from the 4 major viral serotypes.
23 ined maternal and perinatal outcomes and GBS serotypes.
24 e in this region has been determined for all serotypes.
25 OPV) for outbreak response considering all 3 serotypes.
26 y was achieved on days 7, 28, and 56 for all serotypes.
27  children younger than 5 years caused by any serotype, 0.16 (0.07-0.40) for disease caused by PCV7 se
28  0.16 (0.07-0.40) for disease caused by PCV7 serotypes, 0.17 (0.07-0.42) for disease caused by 1, 5,
29         We further show that recombinant AAV serotype 1 (rAAV1) transduces ECs of pathologic vessels,
30 eutralizing antibodies that target sigma1 of serotype 1 (T1) and serotype 3 (T3) reoviruses.
31 evolving murine antigenic epitopes on an AAV serotype 1 capsid template can evade NAbs without compro
32 tudy provides evidence that, within the same serotype 1 clonal complex, biological properties differ
33 tes) and Pakistan (Balochistan Province) and serotype 1 wild poliovirus in Pakistan, Afghanistan, and
34 (E1) specific for a potent, fully human DENV serotype 1-specific antibody, termed HM14c10, derived fr
35 ody HM14c10, which potently neutralizes DENV serotype 1.
36 ster than those given the 2 + 1 schedule for serotypes 1 (8.92 mug/mL vs 3.07 mug/mL), 4 (3.43 mug/mL
37 rocesses are surprisingly distinct among AAV serotypes 1 to 12.
38 elope (E) protein of viruses of dengue virus serotypes 1, 2, and 3 targeted by human neutralizing ant
39          We demonstrated that AAV vectors of serotypes 1, 7, 8, and 9 trafficked from the whiskerpad
40 sessed at birth, day (D) 43, and D91 for GBS serotypes; 1 month postdose 3 (D127) for diphtheria; and
41 ents with COPD and challenged with opsonized serotype 14 Streptococcus pneumoniae.
42    Using geolocated genotype (800 cases) and serotype (17,291 cases) data, we show that in Bangkok, T
43                                     In 2003, serotype 19A CC320 isolates containing both mef(E)/mel a
44 eclined in PCV10 and PCV13 counties, whereas serotype 19A increased in PCV10 counties.
45                       Post-PCV13 declines in serotype 19A IPD in persons aged <2 years (IRR, 0.23; CI
46                      Previous studies on AAV serotype 2 (AAV2) showed that assembly takes place in th
47                         Using a dengue virus serotype 2 (DENV-2) vaccine strain (PDK53), we show that
48  deletion variant of the dengue virus (DENV) serotype 2 (DENV2) Tonga/74 strain lacking 30 nucleotide
49 by which several strains of human astrovirus serotype 2 (HAstV-2) are resistant to the potent HAstV-2
50           Using the Streptococcus pneumoniae serotype 2 CPS, which is synthesized by the widespread W
51             Recent detections of circulating serotype 2 vaccine-derived poliovirus in northern Nigeri
52 OPV2 cessation show continued circulation of serotype 2 vaccine-derived polioviruses (VDPVs).
53                  Zika virus and dengue virus serotype 2 were isolated from a patient with travel to H
54 que variants of 3 pneumococcal strains, D39 (serotype 2), WCH43 (serotype 4) and WCH16 (serotype 6A)
55 f a recombinant adenoassociated viral vector serotype 2/5 (rAAV2/5) encoding human alpha-N-acetylgluc
56 es that target sigma1 of serotype 1 (T1) and serotype 3 (T3) reoviruses.
57                  There was no effect against serotype 3.
58                                              Serotypes 3 (n = 38 [36.2%]) and 19A (n = 30 [28.6%]) we
59                                 Pneumococcal serotype 33A has two membrane-bound O-acetyltransferase
60 e 33F survived short-term drying better than serotype 33A.
61 ars not to affect cell wall shielding, since serotypes 33A and 33F exhibit comparable nonspecific ops
62 and adhesion to nasopharyngeal cells, though serotype 33F survived short-term drying better than sero
63                                              Serotypes 33X1 and 33X2 express novel capsule types base
64       Loss of WciG-mediated O-acetylation in serotypes 33X1 and 33X2, however, resulted in a phenotyp
65              The increased prevalence of MDR serotype 35B after the introduction of PCV13 was directl
66                          We studied putative serotype 35B clinical isolates to assess the uniformity
67                  The increasing incidence of serotype 35B disease and emergence of a multidrug-resist
68                     Streptococcus pneumoniae serotype 35B is a nonvaccine serotype associated with hi
69                                              Serotype 35B is thus a likely future vaccine candidate,
70 candidate, but due to their previous rarity, serotype 35B strains have not been scrutinized for under
71   Certain previously rare serotypes, such as serotype 35B, are increasing in prevalence.
72 longing to ST156 (e.g., 9V, 14, and 19A) and serotype 35B.
73 O-acetylation but was otherwise identical to serotype 35B.
74 vely deep-branching lineages associated with serotypes 35B, 15A, and 15BC.
75 e O-acetyltransferase WciG was functional in serotype 35C but nonfunctional in serotype 42 due to a d
76 presence of O-acetyltransferase genes in the serotype 35C cps locus suggested that it could be incomp
77      In addition, the genetic distinction of serotype 35C from the closely related serotype 42 was un
78                         The structure of the serotype 35C polysaccharide was recently reported, but t
79 nal in serotype 42 due to a deletion in wciG Serotype 35C was O-acetylated at the 5- and 6-positions
80 hemical structural, and serological bases of serotypes 35C and 42.
81 le genetic basis, we named its novel capsule serotype 35D.
82 3-specific 5J7 mAb epitope into dengue virus serotype 4 (DENV4).
83 ents, we assess the dynamics of dengue virus serotype 4 during the 2012 outbreak in Rio de Janeiro.
84 eutralizing antibodies and the mechanisms of serotype 4 neutralization are poorly understood.
85 eumococcal strains, D39 (serotype 2), WCH43 (serotype 4) and WCH16 (serotype 6A) in vitro.
86 uman antibodies that neutralize dengue virus serotype 4.
87 ctional in serotype 35C but nonfunctional in serotype 42 due to a deletion in wciG Serotype 35C was O
88                                     However, serotype 42 has only O-acetylation at 3-beta-galactofura
89 ion of serotype 35C from the closely related serotype 42 was unclear, as their reported cps loci are
90  of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted hum
91                                   Adenovirus serotype 5 (Ad5) is one of the most widely used viral ve
92                             Human adenoviral serotype 5 (HAdV-5) vectors have predominantly hepatic t
93  engineered RD and SC versions of adenovirus serotype 6 (Ad6) to express the hemagglutinin (HA) gene
94                                              Serotype 6A declined in PCV10 and PCV13 counties, wherea
95  (serotype 2), WCH43 (serotype 4) and WCH16 (serotype 6A) in vitro.
96          The 2 + 1 schedule was superior for serotypes 6A, 6B, 18C and 23F (adjusted p value range <0
97 ve pneumococcal disease (MR-IPD) due to PCV7 serotypes (6B, 9V, 14, 19F, and 23F).
98                                              Serotype 6C increased in PCV10 counties, but not in PCV1
99 idic linkage to PG was also demonstrated for serotypes 8 and 31, whose reducing end sugars are glucos
100  Overall, 132 isolates from fatal cases were serotyped (88%) and 35 distinct serotypes were identifie
101 specific tetracysteine sequence into the AAV serotype 9 (AAV9) capsid, to permit labelling of viral p
102  MIS, using either an adeno-associated virus serotype 9 (AAV9) gene therapy vector or recombinant pro
103 e dose of intravenous adeno-associated virus serotype 9 carrying SMN complementary DNA encoding the m
104 ac gene editing using adeno-associated virus serotype 9 to deliver a single short guide RNA is target
105        In vivo, AAV9 (adeno-associated virus serotype 9)-mediated cardiac overexpression of Qki5 prev
106     Using intrathecal adeno-associated virus serotype 9-based delivery, the glutamate-gated chloride
107 nd that prior in vivo Adeno-associated virus serotype 9-mediated gene delivery of GJA1-20k to the hea
108  AND Using an in vivo Adeno-associated virus serotype 9-mediated gene transfer system, we confirmed i
109 omplementary adeno-associated viral vectors, serotype-9 (scAAV-9) in spinal cord tissues after intras
110 icrobial-resistant sequence type 156 (ST156) serotype 9V S. pneumoniae in 3 respiratory patients that
111                         Botulinum neurotoxin serotype A (BoNT/A) causes a debilitating and potentiall
112                                         BoNT serotype A (BoNT/A) has the most prolonged or persistent
113                           Recently, the BoNT serotype A (BoNT/A) subtypes A1 and A2 were reported to
114 e GD1a can associate to botulinum neurotoxin serotype A when expressed as individual trisaccharides.
115  inactivated FMDV serotypes (O, A, and Asia1 serotypes) a B cell response to FMDV SAT1 and serotype C
116 ploid isolates of C. neoformans var. grubii (serotype AA) and of hybrids with C. neoformans var. neof
117 hrough the investigation of 12 different AAV serotypes (AAV1 to -12), we find that AAP is not an esse
118 otypes, including the evolutionarily distant serotypes AAV2 and AAV5.
119 ltiple serotypes, including the most studied serotype, AAV2.
120 mpared invasive and noninvasive pneumococcal serotypes according to previous publications.
121  hybrids with C. neoformans var. neoformans (serotype AD) such aneuploidies have resulted in loss of
122 terval: 79-97%) and 80% (46-93%) for PCV7/13 serotypes among Bedouin and Jewish children <12 months o
123 to calculate incidence rate ratios (IRRs) by serotype and age using a Poisson model.
124 s (such as the associations between capsular serotype and lineage) remain in continuous flux.
125  of invasive pneumococcal disease changes by serotype and serogroup.
126  shown the compatibility of capsids from AAV serotypes and homology of recognition sites of AAV Nab l
127 ine association between carried pneumococcal serotypes and respiratory viruses during childhood commu
128 n pneumonia-associated invasive pneumococcal serotypes and RSV detection during CAAP.
129 irus (AAV) therapeutic products of different serotypes and transgenes.
130 ncluding colonization of mothers by invasive serotypes and vertical transmission to babies.
131 2016, 13 468 (94.9%) were characterized with serotyping and 12 235 (86.2%) with antibiotic susceptibi
132  disease (IPD) is usually caused by a single serotype, and dual-serotype IPD is rare.
133 .07-0.42) for disease caused by 1, 5, and 7F serotypes, and 0.41 (0.25-0.69) for that caused by 3, 6A
134 ever, it is unclear whether all pneumococcal serotypes are equally prone to such interaction.
135 ared to PCV7 serotypes, the additional PCV13 serotypes are more likely to cause bacteremic LRTI and e
136                 The four dengue virus (DENV) serotypes are mosquito-borne flaviviruses responsible fo
137 UTR and P1 genomic region in all three Sabin serotypes, as well as vaccine-related viruses with multi
138 ccus pneumoniae serotype 35B is a nonvaccine serotype associated with high rates of penicillin nonsus
139 n MAbs (90.5%) neutralized at least one DENV serotype at concentrations of 1 mug/ml or less; 6 of the
140 ibody levels against each PCV13 pneumococcal serotype at D301.
141 on induced significant IgG responses for all serotypes: at day 30 compared with baseline, O1A titres
142      HCAECs were stimulated with purified Aa serotype b lipopolysaccharide (LPS) (Aa-LPS), heat-kille
143 r switching has occurred between MDR vaccine serotypes belonging to ST156 (e.g., 9V, 14, and 19A) and
144                 Of importance, the predicted serotype-binding affinities and peptide-anchor motifs di
145 otulinum neurotoxins are known to have seven serotypes (BoNT/A-G).
146 cted from challenge with individual virulent serotypes, both in early challenge and after 5 months of
147 ociations exist between lineage and capsular serotype but these can be easily perturbed, such as by v
148 erotypes) a B cell response to FMDV SAT1 and serotype C was induced.
149 s (DENV), yet cross-reactivity with distinct serotypes can precipitate life-threatening clinical dise
150 identified the dominant serotype in multiple serotype carriage.
151 gated the transduction efficiency of 12 rAAV serotypes carrying an enhanced green fluorescent protein
152 f heptavalent PCV (PCV7) use, overall and by serotype category.
153 pe 2 wild poliovirus, 1 of 3 wild poliovirus serotypes causing paralytic polio since the beginning of
154                 Using the changes in vaccine-serotype colonization data, the model-predicted changes
155 ng positive selection, the sequences of PorB serotypes commonly associated with invasive disease are
156 rs (6.1-16.6) for the grouped six additional serotypes contained in the 13-valent PCV (PCV13) but not
157                       Disease due to grouped serotypes contained in the 23-valent pneumococcal polysa
158 redible interval [CrI] 7.8-10.3) for grouped serotypes contained in the seven-valent PCV (PCV7), and
159 mococcal disease caused by the additional 11 serotypes covered by PPV23 but not PCV13.
160  DENV2, and DENV3 were mainly neutralized by serotype cross-reactive antibodies.
161 erum samples to estimate the contribution of serotype-cross-reactive and type-specific antibodies to
162             Of the 92 serologically distinct serotypes currently defined, 49 serotypes were included
163 contrast, synapses fully intoxicated by BoNT serotypes D or E were refractory to synaptic rescue by a
164          High prevalence worldwide, and more serotype data, are relevant to prevention efforts.
165 veillance and disease control in addition to serotyping data.
166          Dengue, caused by four dengue virus serotypes (DENV-1 to DENV-4), is a highly prevalent mosq
167  and effective against all four dengue virus serotypes (DENV-1-4) in recipients of all ages.
168 em and is caused by four dengue virus (DENV) serotypes (DENV1-4).
169             These observations highlight the serotype-dependent heterogeneity of the capsid assembly
170                             To explain these serotype-dependent protective capacities, many studies h
171 , using liver-targeted adenoassociated virus serotype DJ/8 (AAV-DJ/8) in BTBR wild-type and BTBR Lep(
172  more colony-forming units per mL of vaccine-serotype E coli was noted in the vaccine compared with t
173           However, other macrolide-resistant serotypes (eg, 15A and 35B) not currently represented in
174 ine containing the O-antigens of four E coli serotypes (ExPEC4V).
175 potentially acquire advantages from parental serotypes for enhancement of AAV transduction and evasio
176               To date, at least 27 different serotypes have been recognized.
177  as a critical entry receptor, different AAV serotypes have evolved distinctive interactions with the
178 sponse, however, the relative prevalences of serotypes have shifted.
179 h are constructed against the most prevalent serotypes, have caused great reductions in pneumococcal
180 a small-scale immunoisolation of the antigen serotypes HLA-A*02:01 and HLA-B*27:05 expressed on the E
181 5.0 mug of each of 3 CRM197-glycoconjugates (serotypes Ia, Ib, and III), or placebo.
182 1.5%) dominated, with 97% of cases caused by serotypes Ia, Ib, II, III, and V.
183 ity assessment (EQA) scheme for pneumococcal serotype identification has been performed over a period
184                                              Serotype III (61.5%) dominated, with 97% of cases caused
185                 We found that covR-deficient serotype III S. agalactiae 874391 was significantly atte
186                                              Serotype III, associated with invasive disease, accounts
187                  UAD identified the dominant serotype in multiple serotype carriage.
188 types were common among isolates of the same serotype in South Africa.
189 e incidence of UTIs caused by E coli vaccine serotypes in each group.
190 reased by 30% compared with 76% for non-PCV7 serotypes in equivalent period of vaccine use.
191              Nasopharyngeal carriage of PCV7 serotypes in Group 1 was significantly higher than in Gr
192 omparable due to an expansion of non-vaccine serotypes in Groups 2 and 3.
193 N: Our findings show that for nine of the 13 serotypes in PCV13, post-booster responses in infants pr
194 ical presentation varied with age but not by serotypes in the different conjugate vaccines.
195 urinary antigen detection (UAD) assay for 13 serotypes included in the pneumococcal conjugate vaccine
196                       Furthermore, other AAV serotypes, including AAV1 and -8, require a combination
197 duction of vectors derived from multiple AAV serotypes, including the evolutionarily distant serotype
198 r (AAVR) is a key host receptor for multiple serotypes, including the most studied serotype, AAV2.
199                         IPD due to non-PCV13 serotypes increased by 30% compared with 76% for non-PCV
200 ive pneumococcal disease caused by non-PCV13 serotypes increased, which suggests serotype replacement
201 gue virus NS5 also binds SLAs from different serotypes, indicating that NS5 recognizes the overall sh
202  of two or more doses of PCV13 against PCV13-serotype invasive pneumococcal disease was 85% (95% CI 3
203 data, the model-predicted changes in vaccine-serotype IPD incidence rates were similar to the observe
204 sually caused by a single serotype, and dual-serotype IPD is rare.
205 Of 701 accessory genes identified among dual-serotype IPD isolates, four were common between isolate
206       To assess factors associated with dual-serotype IPD, patient information obtained through labor
207  and find that the duration of carriage of a serotype is indeed positively correlated with the preval
208                      Vaccination against all serotypes is necessary to protect susceptible animals an
209 by this vaccine against the four circulating serotypes is uneven.
210 FMDV), particularly strains of the O and SAT serotypes, is notoriously unstable.
211                                              Serotype IV accounted for 6% of the colonizing isolates,
212 which is considered to be the main driver of serotype IV GBS expansion in North America.
213                              The majority of serotype IV isolates belonged to sequence type (ST)459,
214 duration is currently only understood at the serotype level.
215 reased production of SPN and SLO in epidemic serotype M1 and M89 S. pyogenes strains is associated wi
216                  RocA reduces the ability of serotype M1 GAS isolates to express capsule and to evade
217 type-specific regulator mutations focuses on serotype M3 GAS isolates, and how the identified rewirin
218                  When introduced into an emm serotype-matched invasive strain, the carrier allele (th
219 fied rewiring of regulatory networks in this serotype may be contributing to a decades old epidemiolo
220 the isolates (n = 172) identified all 10 GBS serotypes, most commonly types Ia (40% [69/172 isolates]
221 data on incidence (n = 90), CFR (n = 64), or serotype (n = 45).
222 d for M3 or M18 GAS due to isolates of these serotypes naturally harboring mutant rocA alleles.
223 tx1 or stx2 or were found to be positive for serotype O:157 when analyzed using alternative molecular
224  and 99.3% specific for detection of E. coli serotype O:157.
225 ogy and virulence of Yersinia enterocolitica serotype O:3.
226 culation of three different inactivated FMDV serotypes (O, A, and Asia1 serotypes) a B cell response
227 ues, is present in EPEC strains belonging to serotype O55:H7.
228 e to Streptococcus pneumoniae, trends in the serotype of invasive pneumococci, and invasive pneumococ
229                                Although some serotypes of AAV are known to have nerve tropism, whethe
230                        Among the seven major serotypes of BoNT/A-G, BoNT/A poses the most serious thr
231        It is well established that all seven serotypes of BoNTs (BoNT/A-G) require complex gangliosid
232 s reduced cross-reactivity between different serotypes of dengue and also between a single-mutation a
233 infection or vaccination.IMPORTANCE The four serotypes of dengue virus are the causative agents of de
234 where conserved sequences present in all the serotypes of Dengue virus has been employed for fabricat
235 V developed neutralizing antibodies to all 4 serotypes of DENV.
236 rovided therapeutic effects against all four serotypes of DENV.
237 explaining the long-term coexistence of many serotypes of major- and minor-group RVs.
238 iable, a feature used for identification and serotyping of various GAS strains.
239        For 30 (91%) of 33 patients with dual serotypes, one or both isolates were a pneumococcal conj
240 03), when most deaths were due to nonvaccine serotypes or in neonates.
241   The introduction of a vaccine targeting 13 serotypes (PCV13) in 2010 has led to concern that this s
242 ormally sterile body fluids, reconfirmed and serotyped pneumococcal isolates, and established antimic
243 nd provides a national reference service for serotyping pneumococcal isolates in England and Wales.
244 pisodes historically associated with vaccine-serotype pneumococci may impact the susceptibility of ch
245               Hospitalization rates of PCV13 serotype pneumonia decreased from 47.2 to 15.7 per 10000
246  distinct serotypes were identified, with no serotype predominance.
247  strains belonging to the K1 and K2 capsular serotypes, predominantly in eastern Asia.
248  of incidence, case fatality risk (CFR), and serotype prevalence.
249 r settings would depend on age of IPD onset, serotype profile, and timeliness of vaccination.
250                              For non-vaccine serotypes, rates of progression among Bedouin and Jewish
251 t persist 2 years postvaccination for all 13 serotypes, regardless of age and comorbidity.
252  efficacy against each of the 4 dengue virus serotypes remains to be definitively determined.
253                                   To prevent serotype replacement, reduce transmission, and limit the
254 on-PCV13 serotypes increased, which suggests serotype replacement.
255 ntibodies (Abs) that strongly neutralize the serotype responsible for infection.
256 accine-targeted and non-vaccine pneumococcal serotypes showed lower rates of progression to complex O
257  of neutralization activity against all four serotypes simultaneously.
258                           Till date, majorly serotype specific biosensors for dengue detection have b
259 he possibility of false result as in case of serotype specific DNA sensor.
260 ycoconjugate GBS vaccine elicited higher GBS serotype-specific antibody levels in infants until 90 da
261 ruited to the study (n=40 [20%]), functional serotype-specific antibody was similar between schedules
262 he first few weeks of life, whereas maternal serotype-specific anticapsular antibody is associated wi
263 kinetics of transplacentally transferred GBS serotype-specific capsular antibodies in the infants and
264                Adjusted odd ratios (ORs) for serotype-specific carriage rates by presence of specific
265 d indirect effectiveness of PCV by analyzing serotype-specific colonization prevalence and IPD incide
266 to -12 are all localized in the nucleus with serotype-specific differential patterns of nucleolar ass
267 led understanding of the fine specificity of serotype-specific human antibodies is vital for the deve
268                     The primary endpoint was serotype-specific immunoglobulin G concentrations values
269 f the 5J7 quaternary epitope is a target for serotype-specific neutralizing antibodies after DENV3 in
270                                        PCV13 serotype-specific opsonophagocytic activity (OPA) titers
271           We estimated rates of pneumococcal serotype-specific progression from carriage to disease b
272                                              Serotype-specific protection against Streptococcus pneum
273                            The discussion of serotype-specific regulator mutations focuses on serotyp
274 ker region of seven residues in NS5, rich in serotype-specific residues, is important for the recover
275                                            A serotype-specific urinary antigen detection (UAD) assay
276 NPs of adult C57BL/6 mice with S. pneumoniae serotype (ST) 6A or 8 and then coinfected them with mous
277                      The instability of some serotypes, such as SAT2, affects the quality of vaccines
278                      Certain previously rare serotypes, such as serotype 35B, are increasing in preva
279 s been visualized at a conserved site in two serotypes suggesting a propensity for sulfated-sugar bin
280 ependent enhancement of Dengue-1, 2, 3 and 4 serotypes suggesting that pre-existing immunity to Zika
281 estimates appeared more balanced within each serotype, suggesting that genotype-level heterogeneity m
282 hrough de novo adaptation, with few cases of serotype switching.
283  cell response are similar for all four FMDV serotypes tested following a homologous FMDV vaccination
284 V13) was designed to include disease-causing serotypes that are important in low-income and middle-in
285 bute to the very large numbers of rhinovirus serotypes that coexist while differing in virulence.IMPO
286    PCV failure is rare and, compared to PCV7 serotypes, the additional PCV13 serotypes are more likel
287  involvement of specific clones or O-antigen serotypes, the presence of certain horizontally acquired
288 Prevnar13 that contains CPS antigens from 13 serotypes undergo modifications or degradation during is
289 fant invasive GBS disease and the associated serotypes, updating previous estimates.
290 nce of capsid assembly processes of these 12 serotypes using combinatorial approaches that involved i
291 forming units per mL), the number of vaccine serotype UTIs did not differ significantly between group
292                                              Serotypes VI-IX are more common in Asia.
293                     In 2014, the most common serotypes were 3, 19A and 35B.
294                          Only six Salmonella serotypes were detected.
295 l cases were serotyped (88%) and 35 distinct serotypes were identified, with no serotype predominance
296               The most frequently identified serotypes were III (25%), Ia (23%), and V (19%).
297 lly distinct serotypes currently defined, 49 serotypes were included in the rounds.
298                             The incidence of serotypes, where the effect of the vaccines differed, wi
299                                Isolates were serotyped with the Quellung reaction or PCR.
300 scuous in promoting capsid assembly of other serotypes, with the exception of AAP4, -5, -11, and -12;

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top